Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study

Young, Rowan D.; Litière, Saskia; Lia, Michela; Hogendoorn, Pancras C.W.; Fisher, Cyril; Mechtersheimer, Gunhild; Daugaard, Søren; Sciot, Raf; Collin, Françoise; Messiou, Christina; Grünwald, Viktor; Gronchi, Alessandro; Graaf, Winette van der; Wardelmann, Eva; Judson, Ian

doi:10.1080/0284186x.2017.1315173

Cited by 33 publications

(34 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This practice is based on the subgroup analysis of the phase 3 EORTC 62012 randomized trial, which compared doxorubicin alone versus doxorubicin plus ifosfamide as first‐line treatment in advanced‐stage or metastatic STS. The results demonstrated that liposarcoma had a better tumor response to chemotherapy compared with other histiotypes 202 . Several other studies have further supported the use of doxorubicin‐based therapy, particularly in patients with MLS/RCLS 108,203 …”

Section: Update On Therapy In the Advanced Stagementioning

confidence: 81%

Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine

Gamboa

Gronchi

Cardona

2020

CA A Cancer J Clinicians

Self Cite

344

340

View full text Add to dashboard Cite

Soft-tissue sarcomas (STS) are rare tumors that account for 1% of all adult malignancies, with over 100 different histologic subtypes occurring predominately in the trunk, extremity, and retroperitoneum. This low incidence is further complicated by their variable presentation, behavior, and long-term outcomes, which emphasize the importance of centralized care in specialized centers with a multidisciplinary team approach. In the last decade, there has been an effort to improve the quality of care for patients with STS based on anatomic site and histology, and multiple ongoing clinical trials are focusing on tailoring therapy to histologic subtype. This report summarizes the latest evidence guiding the histiotype-specific management of extremity/truncal and retroperitoneal STS with regard to surgery, radiation, and chemotherapy.

show abstract

Section: Update On Therapy In the Advanced Stagementioning

confidence: 81%

Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine

Gamboa

Gronchi

Cardona

2020

CA A Cancer J Clinicians

Self Cite

344

340

View full text Add to dashboard Cite

show abstract

“…34 In the European Organization for Research and Treatment of Cancer (EORTC) 62012 phase III trial, post hoc subgroup analysis indicated no improvement in response rate or overall survival (OS) in patients with LPS treated with combination doxorubicin-ifosfamide compared with doxorubicin alone. 35 LPS-specific efficacy data are currently unavailable for olaratumab, a PDGFRA-targeting monoclonal antibody recently approved in combination with doxorubicin for untreated advanced STS on the basis of improved OS compared with doxorubicin alone in a randomized phase II trial 36 . Meanwhile, there is clinical evidence that LPS subtypes have differential sensitivity to other available systemic therapies (Table 2).…”

Section: Current Managementmentioning

confidence: 99%

Clinical and Molecular Spectrum of Liposarcoma

Lee

Thway

Huang

et al. 2018

JCO

225

245

View full text Add to dashboard Cite

Liposarcomas are rare malignant tumors of adipocytic differentiation. The classification of liposarcomas into four principal subtypes reflects the distinct clinical behavior, treatment sensitivity, and underlying biology encompassed by these diseases. Increasingly, clinical management decisions and the development of investigational therapeutics are informed by an improved understanding of subtype-specific molecular pathology. Well-differentiated liposarcoma is the most common subtype and is associated with indolent behavior, local recurrence, and insensitivity to radiotherapy and chemotherapy. Dedifferentiated liposarcoma represents focal progression of well-differentiated disease into a more aggressive, metastasizing, and fatal malignancy. Both of these subtypes are characterized by recurrent amplifications within chromosome 12, resulting in the overexpression of disease-driving genes that have been the focus of therapeutic targeting. Myxoid liposarcoma is characterized by a pathognomonic chromosomal translocation that results in an oncogenic fusion protein, whereas pleomorphic liposarcoma is a karyotypically complex and especially poor-prognosis subtype that accounts for less than 10% of liposarcoma diagnoses. A range of novel pharmaceutical agents that aim to target liposarcoma-specific biology are under active investigation and offer hope of adding to the limited available treatment options for recurrent or inoperable disease.

show abstract

“…The UPS subtype has been included in almost all clinical trials that led to the approval of second line therapies. Anthracyclines, ifosfamide, gemcitabine and trabectedin are active drugs in this histology but UPS is primarily sensitive to the combination of doxorubicin and ifosfamide (86). Based on a phase II study, the combination of gemcitabine with docetaxel was considered to be active in UPS (83), but later a larger phase III study confirmed that the combination of epirubicin with ifosfamide was more effective (87).…”

Section: Chemotherapy and Targeted Therapy For Metastatic Sts Of The mentioning

confidence: 99%

Soft tissue sarcomas of the upper extremities: Maximizing treatment opportunities and outcomes (Review)

2019

View full text Add to dashboard Cite

Soft tissue sarcomas (STS) are rare tumors; they do not even equate to 1% of all malignant tumor cases. One-fifth of all STS occur in the upper extremities, where epithelioid sarcoma, synovial sarcoma, clear cell sarcoma and malignant fibrohistiocytoma are the most frequent subtypes. Surgical resection is the cornerstone of treatment. However, accomplishment of optimal oncological and functional results of STS of the upper extremities may represent a challenge for hand surgeons, due to the complex anatomy. In several cases, preoperative therapies are needed to facilitate tumor resection and improve the oncological outcome. Oligometastatic disease may also be a challenging scenario as curative strategies can be applied. Radiotherapy and chemotherapy are commonly used for this purpose albeit with conflicting evidence. Novel drug combinations have also been approved in the metastatic setting, further improving the quality of life and survival of eligible patients. Thus, prior to any approach, every case should be individually discussed in sarcoma centers with specialized multidisciplinary tumor boards. The aim of the present review was to gather the multidisciplinary experiences of the available therapeutic strategies for STS of the upper extremities.

show abstract

Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study

Abstract: Prospective central pathology review of tumor histology should be integrated into future STS clinical trials. Doxorubicin-ifosfamide may be most appropriate for young, fit patients with poorly differentiated Grade III tumors including UPS.

Cited by 33 publications

References 21 publications

Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine

Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine

Clinical and Molecular Spectrum of Liposarcoma

Soft tissue sarcomas of the upper extremities: Maximizing treatment opportunities and outcomes (Review)

Contact Info

Product

Resources

About